** Shares of medical equipment maker Revvity RVTY.N rise 6% to $110.40 in extended trading
** Expects 2025 adjusted EPS to exceed its forecast range of $4.90 to $5 given in October
** Sees preliminary Q4 revenue of $772 million vs estimates of $760.3 million - data compiled by LSEG
** RVTY will report Q4 and full-year results on February 2
** Stock was down 13% in 2025
(Reporting by Koyena Das in Bengaluru)
((koyena.das@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.